| Name | Title | Contact Details |
|---|
Hitachi Chemical Diagnostics Inc is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Abbott Home Health Care Inc is a Stoughton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a developer, manufacturer and marketer of prefabricated, semi-custom and custom orthoses. Orthomerica is known for providing exceptional customer service, quality, innovation and prompt delivery of orthopaedic braces to the orthotics and
Listening to your body is one thing, understanding what it is telling you is an altogether different story. Polar helps you get under the skin of your training. We put it down to a combination of expertise in sports, physiology and electronics, coupled with a deep understanding of customer needs. It`s no surprise then that we`ve been leading the way in technological innovations and heart rate monitors since 1977. And we cater for all levels of fitness by offering a comprehensive product range, along with essential support and advice. Everything from improving an athlete`s sports performance to helping people enjoy a healthier lifestyle, and aiding rehabilitation and weight management. This desire to be the best is made possible by ambitious and highly talented professionals who still believe as passionately in what we do today, as we did over 30 years ago. And our success is clear to see. Today, Polar employs 1200 people worldwide, has 26 subsidiaries globally and manages a distribution network supplying over 35,000 retail outlets in more than 80 countries. Now that`s what we call the power behind Polar.
Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.